3 High-Flying Stocks We Approach with Caution

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

Separating true intrinsic value from speculation isn’t easy, especially during bull markets. That’s where StockStory comes in – to help you find high-quality companies that will stand the test of time. Keeping that in mind, here are three high-flying stocks where the price is not right and some other investments you should look into instead.

Hyatt Hotels (H)

Forward P/E Ratio: 46.4x

Founded in 1957, Hyatt Hotels (NYSE:H) is a global hospitality company with a portfolio of 20 premier brands and over 950 properties across 65 countries.

Why Should You Sell H?

1. Sales trends were unexciting over the last two years as its 3.3% annual growth was below the typical consumer discretionary company

2. Poor free cash flow margin of 2.8% for the last two years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends

3. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Hyatt Hotels is trading at $181.12 per share, or 46.4x forward P/E. Read our free research report to see why you should think twice about including H in your portfolio, it’s free.

Bio-Techne (TECH)

Forward P/E Ratio: 35.7x

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Why Do We Think TECH Will Underperform?

1. Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth

2. Modest revenue base of $1.22 billion gives it less fixed cost leverage and fewer distribution channels than larger companies

3. Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results

At $72.42 per share, Bio-Techne trades at 35.7x forward P/E. If you’re considering TECH for your portfolio, see our FREE research report to learn more.

Patterson-UTI (PTEN)

Forward P/E Ratio: 54.3x

Operating 135 Tier-1 super-spec rigs that can handle the industry’s most demanding drilling projects, Patterson-UTI (NASDAQ:PTEN) provides contract drilling rigs, hydraulic fracturing, and drill bits to oil and gas operators.

Why Do We Think Twice About PTEN?

1. Gross margin of 29.9% is below its competitors, leaving less money to invest in exploration and production

2. EBITDA margin failed to increase over the last five years, indicating the company couldn’t optimize its expenses

3. Low free cash flow margin of 5.8% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders

Patterson-UTI’s stock price of $11.35 implies a valuation ratio of 54.3x forward P/E. Dive into our free research report to see why there are better opportunities than PTEN.

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.